Literature DB >> 28607097

Correction: Adaptive Reprogramming of De Novo Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer.

.   

Abstract

Entities:  

Year:  2017        PMID： 28607097     DOI： 10.1158/2159-8290.CD-17-0565

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


× No keyword cloud information.
  2 in total

1.  Identification of BBOX1 as a Therapeutic Target in Triple-Negative Breast Cancer.

Authors:  Chengheng Liao; Yang Zhang; Cheng Fan; Laura E Herring; Juan Liu; Jason W Locasale; Mamoru Takada; Jin Zhou; Giada Zurlo; Lianxin Hu; Jeremy M Simon; Travis S Ptacek; Victor G Andrianov; Einars Loza; Yan Peng; Huanghe Yang; Charles M Perou; Qing Zhang
Journal:  Cancer Discov       Date:  2020-07-20       Impact factor: 38.272

2.  Metabolic profiles of triple-negative and luminal A breast cancer subtypes in African-American identify key metabolic differences.

Authors:  Fariba Tayyari; G A Nagana Gowda; Olufunmilayo F Olopade; Richard Berg; Howard H Yang; Maxwell P Lee; Wilfred F Ngwa; Suresh K Mittal; Daniel Raftery; Sulma I Mohammed
Journal:  Oncotarget       Date:  2018-02-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.